UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
6-K
REPORT
OF FOREIGN PRIVATE ISSUER
PURSUANT
TO RULE 13a-16 OR 15d-16
UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For
the Month of January 2025
Commission
File Number: 001-40303
Inspira
Technologies Oxy B.H.N. Ltd.
(Translation
of registrant’s name into English)
2
Ha-Tidhar St.
Ra’anana
4366504, Israel
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
☒ Form
20-F ☐ Form 40-F
CONTENTS
On
January 7, 2025, Inspira Technologies Oxy B.H.N. Ltd., or the Registrant, issued a press release titled “Inspira™ Technologies
Flagship Technology to be Showcased at Arab Health Expo 2025 in Dubai,” a copy of which is furnished as Exhibit 99.1
with this report of foreign private issuer on Form 6-K.
The
first four paragraphs and the section titled “Forward-Looking Statements” in the press release are incorporated by
reference into the Registrant’s Registration Statements on Form F-3 (Registration No. 333-266748) and Form S-8 (Registration
Nos. 333-259057 and 333-277980), filed with the Securities and Exchange Commission, to be a part thereof from the date on which this
Report of Foreign Private Issuer on Form 6-K is submitted, to the extent not superseded by documents or reports subsequently filed or
furnished.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.
| |
Inspira Technologies Oxy B.H.N. Ltd. |
| |
|
|
| Date: January 7, 2025 |
By: |
/s/ Dagi Ben-Noon |
| |
|
Name: |
Dagi Ben-Noon |
| |
|
Title: |
Chief Executive Officer |
2
Exhibit 99.1
Inspira™ Technologies Flagship
Technology to be Showcased at Arab Health Expo 2025 in Dubai
Visitors at Glo-Med Network Inc’s
booth can explore Inspira’s cutting-edge respiratory solutions, with the FDA-cleared INSPIRA™ ART100, showcasing the
future of respiratory care
RA’ANANA, Israel – January 7, 2025
– Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ: IINN, IINNW), (“Inspira Technologies,” “Inspira” or the
“Company”), a groundbreaking respiratory support technology company, is pleased to announce that the INSPIRA™ ART100,
a cardiopulmonary bypass system will be showcased at Arab Health 2025, one of the largest healthcare exhibitions in
the Middle East, expected to have over 3,800 exhibitors and over 180 visiting countries.
The event will take place from January 27th to January
30th, 2025 at the Dubai World Trade Center, in Dubai, United Arab Emirates.
The INSPIRA ART100 system has already attained U.S. Food and Drug
Administration (“FDA”) clearance for Cardiopulmonary Bypass procedures. The INSPIRA ART100 system utilizes
a technique that adds oxygen to the blood and removes carbon dioxide, with the enriched blood being circulated back to the patient, taking
over the functionality of the heart and/or lungs in critical care patients.
The INSPIRA ART100 is equipped with the Company’s signature proprietary
software designed to assist medical teams to navigate through the setup process, as well as advanced features that include customizing
procedures for improved patient care. It is also equipped with a built-in alarm management that offers immediate troubleshooting solutions
to the medical team. The system has a small footprint, provides up to four hours of uptime in emergency scenarios, and can be used with
various disposables available on the market.
Dagi Ben-Noon, CEO of Inspira Technologies said:
“The Arab Health Expo 2025 in Dubai serves as a global platform to present
our innovative technologies to healthcare leaders and companies from around the world. This is an incredible opportunity to explore new
markets and forge partnerships that can drive the global adoption of our cutting-edge respiratory solutions.”
About the Arab Health Conference
Arab Health 2025 is the leading healthcare exhibition and congress
in the Middle East, bringing together global healthcare professionals, manufacturers, and innovators to showcase cutting-edge medical
technologies, products, and services.
Inspira™ Technologies OXY B.H.N. Ltd.
Inspira Technologies is an innovative medical technology company in
the life support and respiratory treatment arena. The Company has developed a breakthrough Augmented Respiration Technology (INSPIRA™
ART), a groundbreaking device poised to revolutionize the $19 billion mechanical ventilation market. With 20 million intensive
care unit patients with acute respiratory failure each year, many of whom rely on mechanical ventilators, the INSPIRA ART offers a potential
alternative by elevating and stabilizing decreasing oxygen saturation levels in minutes without a ventilator, with patients being awake
during treatment. The INSPIRA ART is being equipped with a clip-on HYLA™ blood sensor, a real-time continuous blood monitoring technology,
aiming to alert physicians of changes in a patient’s condition without the need for intermittent actual blood samples, aiming to support
physicians in making informed decisions.
In June and July 2024, respectively, the Company’s INSPIRA™ ART100
system has obtained FDA 510(k) clearance for use in CBP procedures, along with the Israeli AMAR certification for both Extra-Corporeal
Membrane Oxygenation and Cardiopulmonary Bypass procedures.
The Company’s other products and technologies, including the
INSPIRA ART also known as the INSPIRA™ ART500 or Gen 2, the INSPIRA™ Cardi-ART portable modular device, VORTX™ Oxygen
Delivery System, and HYLA™ blood sensor, are currently being designed and developed, and have not yet been tested or used in humans
nor approved by any regulatory entity.
For more information, please visit our corporate website at https://inspira-technologies.com
Forward-Looking Statements
This press release
contains express or implied forward-looking statements pursuant to U.S. Federal securities laws. These forward-looking statements and
their implications are based on the current expectations of the management of the Company only and are subject to a number of factors
and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. For example,
the Company is using forward-looking statements when it discusses the potential benefits of its products and technologies, that Arab Health 2025 is an incredible opportunity to explore new markets and forge partnerships that can drive the global adoption of
the Company’s cutting-edge respiratory solutions, the size of
its target market and that its development of innovative life support technology could disrupt the $19 billion mechanical ventilation
market. These forward-looking statements and their implications are based solely on the current expectations of the Company’s management
and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in
the forward-looking statements. Except as otherwise required by law, the Company undertakes no obligation to publicly release any revisions
to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated
events. More detailed information about the risks and uncertainties affecting the Company is contained under the heading “Risk Factors”
in the Company’s annual report on Form 20-F for the fiscal year ended December 31, 2023 filed with the U.S. Securities and Exchange Commission
(the “SEC”), which is available on the SEC’s website at www.sec.gov.
Contact:
For more information, contact:
Inspira Technologies – Media Relations
Email: info@inspirao2.com
Phone: +972-9-9664485
MRK-ARS-122
Copyright © 2018-2025 Inspira Technologies OXY B.H.N. LTD., All
rights reserved.
Inspira Technologies Oxy... (NASDAQ:IINNW)
Gráfico Histórico do Ativo
De Dez 2024 até Jan 2025
Inspira Technologies Oxy... (NASDAQ:IINNW)
Gráfico Histórico do Ativo
De Jan 2024 até Jan 2025
